- Home
- DVA vs SNN Comparison
DVA vs SNN Comparison
Compare DVA & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVA
- SNN
- Stock Information
- Founded
- DVA 1994
- SNN 1856
- Country
- DVA United States
- SNN United Kingdom
- Employees
- DVA N/A
- SNN N/A
- Industry
- DVA Misc Health and Biotechnology Services
- SNN Industrial Specialties
- Sector
- DVA Health Care
- SNN Health Care
- Exchange
- DVA Nasdaq
- SNN Nasdaq
- Market Cap
- DVA 10.9B
- SNN 12.6B
- IPO Year
- DVA 1995
- SNN 1999
- Fundamental
- Price
- DVA $142.56
- SNN $30.28
- Analyst Decision
- DVA Hold
- SNN Hold
- Analyst Count
- DVA 4
- SNN 3
- Target Price
- DVA $157.00
- SNN $27.50
- AVG Volume (30 Days)
- DVA 857.4K
- SNN 915.5K
- Earning Date
- DVA 08-05-2025
- SNN 07-31-2025
- Dividend Yield
- DVA N/A
- SNN 2.38%
- EPS Growth
- DVA 14.90
- SNN 56.15
- EPS
- DVA 10.11
- SNN 0.47
- Revenue
- DVA $12,968,524,000.00
- SNN $5,810,000,000.00
- Revenue This Year
- DVA $6.46
- SNN $6.87
- Revenue Next Year
- DVA $3.24
- SNN $5.19
- P/E Ratio
- DVA $14.10
- SNN $32.11
- Revenue Growth
- DVA 5.11
- SNN 4.70
- 52 Week Low
- DVA $131.76
- SNN $23.69
- 52 Week High
- DVA $179.60
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- DVA 55.72
- SNN 60.00
- Support Level
- DVA $135.07
- SNN $29.99
- Resistance Level
- DVA $147.45
- SNN $30.77
- Average True Range (ATR)
- DVA 3.05
- SNN 0.40
- MACD
- DVA 0.82
- SNN 0.04
- Stochastic Oscillator
- DVA 61.83
- SNN 79.32
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.